Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide…
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
Press Release Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA…
Bybit Private Wealth Management Sustains Positive Momentum in January 2026
DUBAI, UAE, Feb. 11, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency…
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
February 11, 2026 06:00 ET | Source: Upstream Bio – Verekitug provided…
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today…
MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer’s Disease
TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology…
ALK receives positive recommendation for EURneffy 1 mg: A needle-free anaphylaxis treatment for children
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the…
Trisol Medical Announces Positive Results from U.S. Early Feasibility Study of Its Transcatheter Tricuspid Valve Replacement System
Results demonstrate a favorable safety profile and functional improvements in patients with…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
